Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 1 October 2009, doi:10.1136/bmj.b3540
Cite this as: BMJ 2009;339:b3540
Mona Nabulsi, associate professor of paediatrics; head of division of general paediatrics
1 Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, American University of Beirut, PO Box 113-6044/C8, Beirut, Lebanon
Correspondence to: M Nabulsi mn04@aub.edu.lb
| The first 150 words of the full text of this article appear below. |
Although fever is a beneficial host response, it is an important cause of anxiety for parents and doctors. The quest for effective treatment has led to new combination regimens of antipyretic drugs for febrile children. These are popular among caregivers and healthcare providers,1 2 3 4 but they have been tested in clinical trials only recently.4 5 6 7 8 The new regimens consist of combinations of ibuprofen and paracetamol (acetaminophen) given at variable time schedules. The main concern about these treatments is safety, because they may increase the risk of renal toxicity, as a result of reduced glutathione in the kidney and tubular necrosis,9 10 or the risk of infection with invasive group A streptococci.11 We therefore need to know whether these combinations are more effective than, and as safe as, monotherapy in children with fever.
A systematic search of PubMed, Medline, CINAHL, Cochrane, and Embase databases for systematic reviews and randomised clinical trials, published in any
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses